Genmab, AbbVie Lymphoma Drug Hits Phase 3 Goal
On air: Hank Ledger, Vera Bullock and Dale Bearman on Market HoursPublished
At a glance
- First reported by GlobeNewswire Inc.: “Genmab and AbbVie Announce Epcoritamab in Combination with R-CHOP Demonstrates Statistically Significant Improvement in Progression-Free Survival in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma”.
- Covered on BBN on Monday, October 5, 2026, at 3:23 PM ET on Market Hours, by Hank Ledger, Vera Bullock and Dale Bearman.
- Topics: AbbVie, Genmab.
The real story
The reporting behind this segment. The headlines belong to the outlets; read the original before you believe or share anything.
- GlobeNewswire Inc.Genmab and AbbVie Announce Epcoritamab in Combination with R-CHOP Demonstrates Statistically Significant Improvement in Progression-Free Survival in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma
The story so far
- Genmab, AbbVie Lymphoma Drug Hits Phase 3 Goal (this story)
- Genmab, AbbVie Lymphoma Data Lifts Epkinly Outlook · Seeking Alpha
- AbbVie Cuts Guidance; Bond Rout Draws Savers · Benzinga
- AI Chips Surge, AbbVie Cancer Combo, Cowbell Mystery · Bloomberg.com
- Europe Climbs as Genmab Jumps and Bond Yields Retreat · Reuters
From the archive: everything BBN aired on Monday, October 5, 2026 · the U.S. archive · all months
More in U.S.
All U.S. →
WORKERS UNITE
America's Gig Workers Turn to an Old-School Union
Tens of thousands of Uber and Lyft drivers in California are unionizing as fuel costs erode their earnings; the gig economy meets traditional labor…
CRIME WATCH
Fairfax officer, 23-year veteran, charged with shoplifting
The officer allegedly shoplifted from two Target stores; the department has not disclosed what items were taken.